MannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting
November 10 2022 - 5:05AM
MannKind Corporation (Nasdaq: MNKD), a company
focused on the development and commercialization of inhaled
therapeutic products and devices for patients with endocrine and
orphan lung diseases, announced today that it will present data
from two posters on November 10 during the 22nd Annual Diabetes
Technology Meeting’s virtual poster session.
“We are excited to present initial findings from the Afrezza
with Basal Combination (ABC) proof-of-concept study, which
demonstrated significantly improved postprandial glucose excursions
with TI compared to subcutaneous insulin during an in-office meal
challenge,” said Dr. Kevin Kaiserman, Vice President of Medical
Affairs and Safety for MannKind’s Endocrine Business Unit. Dr.
Kaiserman will present poster# DESB2134D, which showed that:
- TI peaked 30 minutes faster and significantly reduced glucose
at 60 minutes compared to subcutaneous insulins – including
recently approved versions.
- The mean PPGE at 60 minutes for TI measured 57.9 mg/dL compared
to 101.4 mg/dL for subcutaneous insulins – a reduction of 43.5
mg/dL.
- No severe hypoglycemia was observed in the TI groups using the
higher dose conversion method described below.
“Providing inhaled insulin as a potential pump-sparing option is
an intriguing finding from this pilot study,” said Michael
Castagna, PharmD, Chief Executive Officer for MannKind Corporation.
“MannKind remains committed to improving options for mealtime
control for patients living with diabetes.”
The ABC study took patients currently using their Automated
Insulin Delivery (AID) device and randomized them into three groups
– a control group that continued to use their system with current
subcutaneous insulin, a second group that added TI for mealtime
insulin in combination with the AID system, and a third group that
used long-acting insulin degludec once a day with TI for all meals
and corrections (instead of the AID system).
Twenty-one adult randomized participants (≥ 18 years) with T1D
and on AID therapy were analyzed at two clinical sites. The
protocol specified administering an identical standardized meal to
each subject who also received a mealtime dose of TI in combination
with their AID. The TI dose was determined by multiplying the
calculated RAA dose by two and rounding down to the nearest
four-unit TI dose (capped at 24 units). Capillary blood glucose
(SMBG) was measured by CONTOUR® meters (Ascensia Diabetes Care,
Parsippany, NJ) immediately before the meal (t = 0; baseline) and
at timepoints 15-, 30-, 45-, 60-, 90-, and 120-minutes relative to
the start of the meal.
Data showing the similar effects of the three treatment groups
on glycemic control are being readied for publication and are
planned to be presented at a diabetes conference in 2023.
MannKind also sponsored Poster# DESB2134D – Simulating the
Impact of Diabetes Therapy Engagement on Outcomes – which will be
presented by Lane Desborough, CEO of Nudge BG.
About MannKindMannKind Corporation (Nasdaq:
MNKD) focuses on the development and commercialization of
innovative therapeutic products and devices to address serious
unmet medical needs for those living with endocrine and orphan lung
diseases.
We are committed to using our formulation capabilities and
device engineering prowess to lessen the burden of diseases such as
diabetes, pulmonary arterial hypertension (PAH) and nontuberculous
mycobacterial (NTM) lung disease. Our signature technologies –
dry-powder formulations and inhalation devices – offer rapid and
convenient delivery of medicines to the deep lung where they can
exert an effect locally or enter the systemic circulation.
With a passionate team of Mannitarians collaborating nationwide,
we are on a mission to give people control of their health and the
freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on
LinkedIn, Facebook, Twitter or Instagram.
Forward-Looking StatementsThis press release
contains forward-looking statements about the implications of
clinical data that involve risks and uncertainties. Words such as
“believes”, “anticipates”, “plans”, “expects”, “intends”, “will”,
“goal”, “potential” and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon MannKind’s current expectations. Actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of
various risks and uncertainties, which include, without limitation,
the risk that continued testing of a drug product may not yield
successful results or results that are consistent with earlier
testing, and other risks detailed in MannKind’s filings with the
Securities and Exchange Commission, including its Annual Report on
Form 10-K for the year ended December 31, 2021 and subsequent
periodic reports on Form 10-Q and current reports on Form 8-K. You
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
All forward-looking statements are qualified in their entirety by
this cautionary statement, and MannKind undertakes no obligation to
revise or update any forward-looking statements to reflect events
or circumstances after the date of this press release.
AFREZZA, TECHNOSPHERE and MANNKIND are registered trademarks of
MannKind Corporation.
For MannKind:
Christie Iacangelo, Corporate Communications
(818) 292-3500
Email: media@mannkindcorp.com
Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jun 2024 to Jul 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jul 2023 to Jul 2024